|
|
Article: Bristol-Myers Squibb and Otsuka Pharmaceutical Spend Nearly Twice as Much on Promotion as Other Drug Companies in the Atypical Antipsychotics Market Yet Gain Minimal Company Recognition Among Physicians.
- Article from:
- PR Newswire
- Article date:
- March 5, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The New Brands & Strategies: Atypical Antipsychotics Report Provides Critical Commercial Analysis at the Market, Company, and Brand Level
WALTHAM, Mass., March 5 /PRNewswire/ -- Decision Resources has produced a new report that finds that Bristol-Myers Squibb and Otsuka Pharmaceutical spend almost twice as much on Abilify's promotion as other marketers of atypical antipsychotics spend promoting their agents. Surprisingly, psychiatrists and primary care physicians surveyed cite Eli Lilly's Zyprexa and AstraZeneca's Seroquel, respectively, as the companies from which they receive the most promotional material, and fewer than 10% mention Bristol- Myers Squibb or ...